Literature DB >> 27727005

Clinical inertia to insulin initiation and intensification in the UK: A focused literature review.

Kamlesh Khunti1, David Millar-Jones2.   

Abstract

Achieving tight glycaemic control early following the diagnosis of type 2 diabetes is key to optimising clinical outcomes, yet many patients and clinicians are reluctant to initiate and intensify insulin therapy. Reasons for this arise primarily from a lack of time, clinical expertise and patient understanding. However, meaningful progress can be achieved with self-management educational programmes soon after diagnosis. Clinician education and training, along with easy-to-use and well-tolerated therapies (for example, those carrying a low risk of hypoglycaemia and/or avoiding weight gain), may also increase the likelihood of patient adherence.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Clinical inertia; Insulin intensification; Type 2 diabetes guidelines

Mesh:

Substances:

Year:  2016        PMID: 27727005     DOI: 10.1016/j.pcd.2016.09.003

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  59 in total

Review 1.  Quality of Diabetes Care in the USA.

Authors:  Ben Alencherry; Dennis Bruemmer
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

2.  Improving Transition to Insulin Through Clinical Conversations.

Authors:  Jana L Wardian
Journal:  Clin Diabetes       Date:  2020-07

3.  Analysis of "Laboratory and Benchtop Performance of a Mealtime Insulin Delivery System".

Authors:  Eric Zijlstra
Journal:  J Diabetes Sci Technol       Date:  2018-04-05

4.  A Behavioral Perspective of Therapeutic Inertia: A Look at the Transition to Insulin Therapy.

Authors:  Susan J Guzman
Journal:  Diabetes Spectr       Date:  2020-02

5.  Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.

Authors:  Muthiah Vaduganathan; Silvio E Inzucchi; Naveed Sattar; David H Fitchett; Anne Pernille Ofstad; Martina Brueckmann; Jyothis T George; Subodh Verma; Michaela Mattheus; Christoph Wanner; Bernard Zinman; Javed Butler
Journal:  Diabetes Obes Metab       Date:  2021-10-07       Impact factor: 6.408

6.  A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes.

Authors:  Melanie Davies; Steve Bain; Guillaume Charpentier; Frank Flacke; Harmonie Goyeau; Michael Woloschak; Christoph Hasslacher; Giacomo Vespasiani; Steven Edelman
Journal:  J Diabetes Sci Technol       Date:  2019-01-15

7.  The Digital/Virtual Diabetes Clinic: The Future Is Now-Recommendations from an International Panel on Diabetes Digital Technologies Introduction.

Authors:  Moshe Phillip; Richard M Bergenstal; Kelly L Close; Thomas Danne; Satish K Garg; Lutz Heinemann; Irl B Hirsch; Boris P Kovatchev; Lori M Laffel; Viswanathan Mohan; Christopher G Parkin; Tadej Battelino
Journal:  Diabetes Technol Ther       Date:  2020-09-28       Impact factor: 6.118

8.  Leveraging Artificial Intelligence to Improve Chronic Disease Care: Methods and Application to Pharmacotherapy Decision Support for Type-2 Diabetes Mellitus.

Authors:  Shinji Tarumi; Wataru Takeuchi; George Chalkidis; Salvador Rodriguez-Loya; Junichi Kuwata; Michael Flynn; Kyle M Turner; Farrant H Sakaguchi; Charlene Weir; Heidi Kramer; David E Shields; Phillip B Warner; Polina Kukhareva; Hideyuki Ban; Kensaku Kawamoto
Journal:  Methods Inf Med       Date:  2021-05-11       Impact factor: 2.176

Review 9.  Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia.

Authors:  Guido Gembillo; Ylenia Ingrasciotta; Salvatore Crisafulli; Nicoletta Luxi; Rossella Siligato; Domenico Santoro; Gianluca Trifirò
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

Review 10.  Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.

Authors:  Juris J Meier
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-25       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.